Key facts
- It has raised $83.0M across 1 recorded rounds; the latest was Seed Round ($4.0M) in Sep 2024.
- Notable investors include Bpifrance, Hybridge Capital Management, Golda Darty Partners, Johnson Financial Group, Cancer Prevention and Research Institute of Texas — 9 tracked in total.
- Invectys has filed 2 Form Ds with the SEC since 2021, most recently Oct 2024 ($4.0M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Invectys
Funding rounds
1 roundsAbout Invectys
Operator of a biopharmaceutical company intended to offer an immunotherapy approach to treat cancer. The company focuses on mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients by targeting a broad-ranging cancer antigen, enabling healthcare practitioners to target telomerase in the cell and improve patients' health.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2010
- Employees
- 19
- Website
- invectys.com/
- Ownership
- Privately Held (backing)
Invectys doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Invectys shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Invectys in its N-PORT filings yet. We sweep new filings monthly.